TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

(ECOG-ACRIN Cancer Research Group) " Before TAILORx, there was uncertainty about the best treatment for women with a mid-range score of 11-25 on the Oncotype DX Breast Recurrence Score test. The trial was designed to address this question, and provides a very definitive answer, " said lead investigator Joseph A. Sparano, MD. " Any woman with early-stage breast cancer 75 years or younger should have the 21-gene expression test and discuss the results with her doctor to guide her decision to the right therapy. "
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news